Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 22, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

CTLA-4Ig: uses and future directions.

Moshe Ben-Shoshan1

  • 1Department of Pediatric Allergy and Immunology, McGill University Health Center, Montreal, QC, Canada. daliamoshebs@gmail.com

Recent Patents on Inflammation & Allergy Drug Discovery
|June 13, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of a Provincial Law to Improve Epinephrine Use for Anaphylaxis in Schools in Alberta, Canada: A Pre-Post Study.

International archives of allergy and immunology·2026
Same author

Why physicians underuse patient-reported outcomes in atopic dermatitis and chronic urticaria - Insights from the UCARE/ADCARE PROMUSE study.

The World Allergy Organization journal·2026
Same author

Eosinophilic Esophagitis following Oral Immunotherapy: A Systematic Review and Meta-Analysis.

International archives of allergy and immunology·2026
Same author

Food protein-induced enterocolitis syndrome (FPIES) among Canadian children living in Montreal.

International archives of allergy and immunology·2026
Same author

Seasonal Peaks and Climatic Predictors of Chronic Urticaria: A Global Google Trends Analysis.

Journal of cutaneous medicine and surgery·2026
Same author

Diagnosis and Management of Comorbid Autoimmune Disorders in Children with Chronic Spontaneous Urticaria.

Journal of inflammation research·2026
Same journal

Childhood Infectious Encephalitis: An Overview of Clinical Features, Investigations, Treatment, and Recent Patents.

Recent patents on inflammation & allergy drug discovery·2020
Same journal

Nummular Eczema: An Updated Review.

Recent patents on inflammation & allergy drug discovery·2020
Same journal

Childhood Alopecia Areata: An Overview of Treatment and Recent Patents.

Recent patents on inflammation & allergy drug discovery·2020
Same journal

Human Ascariasis: An Updated Review.

Recent patents on inflammation & allergy drug discovery·2020
Same journal

Scenario of the Treatment of Arthritis with Natural Products.

Recent patents on inflammation & allergy drug discovery·2020
Same journal

Acute Myocarditis in Children: An Overview of Treatment and Recent Patents.

Recent patents on inflammation & allergy drug discovery·2020
See all related articles

Blocking Cytotoxic lymphocyte-associated molecule-4 (CTLA-4) with CTLA-4Ig shows promise for controlling immune responses. This approach is approved for rheumatoid arthritis and explored for other immune-related conditions.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Cytotoxic lymphocyte-associated molecule-4 (CTLA-4, CD152) is a key regulator in the CD28 receptor family.
  • CTLA-4 interacts with B7 family ligands, B7-1 (CD80) and B7-2 (CD86).
  • Dysregulated immune responses are implicated in various diseases.

Purpose of the Study:

  • To review the role of CTLA-4 in immune regulation.
  • To discuss the therapeutic potential of blocking CTLA-4 interactions.
  • To explore patents and clinical applications of CTLA-4 blockade.

Main Methods:

  • Literature review of CTLA-4 function and therapeutic strategies.
  • Analysis of existing patents related to CTLA-4.
  • Discussion of clinical applications in autoimmune, allergic, and transplantation settings.

More Related Videos

Integrative Toolkit to Analyze Cellular Signals: Forces, Motion, Morphology, and Fluorescence
14:55

Integrative Toolkit to Analyze Cellular Signals: Forces, Motion, Morphology, and Fluorescence

Published on: March 5, 2022

Related Experiment Videos

Last Updated: Jun 22, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

Integrative Toolkit to Analyze Cellular Signals: Forces, Motion, Morphology, and Fluorescence
14:55

Integrative Toolkit to Analyze Cellular Signals: Forces, Motion, Morphology, and Fluorescence

Published on: March 5, 2022

Main Results:

  • CTLA-4 blockade using CTLA-4Ig can modulate immune responses.
  • CTLA-4Ig is FDA-approved for Rheumatoid Arthritis (RA).
  • Investigational uses include other autoimmune diseases, transplantation, and allergies.

Conclusions:

  • CTLA-4 blockade represents a significant therapeutic strategy for immune-mediated diseases.
  • Further research and patent exploration are ongoing for expanded clinical applications.
  • CTLA-4Ig offers a targeted approach to managing immune dysregulation.